Xuanzhu Biopharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2018-09-05
- Employees
- 251
- Market Cap
- -
- Website
- http://www.xuanzhubio.com
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: Placebo + Letrozole/AnastrozoleDrug: XZP-3287+ Letrozole/Anastrozole
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 397
- Registration Number
- NCT05257395
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
Phase 3
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 238
- Registration Number
- NCT05204628
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Chang Chun, Ji Lin, China
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: XZP-3287+Fulvestrant
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05077449
- Locations
- 🇨🇳
Chinese Academy of Medical Science, Beijing, Beijing, China
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
Phase 1
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: XZP-6019 tabletDrug: Placebo
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05063968
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Phase 1
- Conditions
- ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05055232
- Locations
- 🇨🇳
Shanghai Chest hospital affiliated to Shanghai jiao tong university, ShangHai, Shanghai, China
Food Effect and Mass Balance Study of XZP-3621 Tablets
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05034120
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Solid Tumors
- Interventions
- Drug: XZP-5955 tablets
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT04996121
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04951765
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: XZP-3287 combined with rifampicin
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04951713
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
Phase 1
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Drug: XZP-5610 Tablet （for "Part C1"）Drug: XZP-5610 Tablet (for Part B)Drug: XZP-5610 Tablet (for Part A)Drug: Placebo to match XZP-5610 Tablet (for Part B)Drug: Placebo to match XZP-5610 Tablet (for Part A)Drug: XZP-5610 Tablet for "Part C2"
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT04913090
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath